A case-control study in NAT2 gene polymorphism studies in patients diagnosed with acute myeloid leukemia
Acta Biochimica Polonica · 2023
DOI: 10.18388/abp.2020_6235 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift Acta Biochimica Polonica, 2023. Verfasst von Abdullah Farasani. Beteiligte Einrichtung: 1Biomedical Research Unit, Medical Research Center, Jazan University, Saudi Arabia; 2Department of Medical Laboratory Technology, Faculty of Applied …. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Arylamine N-Acetyltransferase. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Acute myeloid leukemia (AML) is a clinically defined heterogeneous disease whose pathophysiology is currently unknown. The association of NAT2 acetylation profiles with human cancer risks, particularly with AML, was investigated in molecular epidemiological studies. Additionally, the NAT2 gene was carried out with acute lymphoid leukemia and other cancers.
Aim
In this case-control study, C481T (rs1799929) and G857A (rs1799931) polymorphism studies were investigated in diagnosed AML patients in the Saudi population.
Methods
This case-control study included 100 AML patients and 100 control subjects recruited in Saudi Arabia. The C481T and G857A polymorphisms were genotyped using specific primers and restriction enzymes. Statistical analysis was performed on the AML patients and controls using chi-square tests, genotyping, and allele frequencies (odds ratios, 95% of confidence intervals, and P-values).
Results
Hardy Weinberg Equilibrium was determined to be both within and outside of the G857A and C481T polymorphisms. The allele and genotyping frequencies in AML and control subjects were analyzed, and the results corroborated the unfavorable connection with C481T (CC vs CT+TT; OR-1.12; (95% CIs: 0.64–1.96); P=0.67 and T vs C; OR-0.89; (95% CIs: 0.59–1.35) and P=0.60) and G857A polymorphisms (GG vs GA+AA; OR-1.50; (95% CIs: 0.83–2.71); P=0.17 and A vs G; OR-0.71; (95%CIs: 0.43–1.19) and P=0.19) in the NAT2 gene.
Conclusion
The study results revealed a negative correlation as well as a protective factor for AML with the C481T and G857A polymorphisms in the NAT2 gene.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Biomedical Research Unit, Medical Research Center, Jazan University, Saudi Arabia; 2Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Jazan University, Saudi Arabia.
Zitieren
APA
Farasani, A. (2023). A case-control study in NAT2 gene polymorphism studies in patients diagnosed with acute myeloid leukemia. Acta Biochimica Polonica. https://doi.org/10.18388/abp.2020_6235
Vancouver
Farasani A. A case-control study in NAT2 gene polymorphism studies in patients diagnosed with acute myeloid leukemia. Acta Biochimica Polonica. 2023. doi:10.18388/abp.2020_6235
BibTeX
@article{Farasani2023,
author = {Farasani, Abdullah},
title = {A case-control study in NAT2 gene polymorphism studies in patients diagnosed with acute myeloid leukemia},
journal = {Acta Biochimica Polonica},
year = {2023},
doi = {10.18388/abp.2020_6235}
}
EUVIMED